Press

Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement

Jul 5 • 5 min read

Quick Take: Cybin has announced that their wholly-owned subsidiary, Adelia Theraputics, has achieved milestones for its pre-clinical trials. Cybin Inc. (NEO:CYBN), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly-controlled subsidiary of Cybin, has achieved certain earn-out milestones for the period commencing January 1, 2021,…

COMPASS Pathways joins forces with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate psychedelic research.

Jul 5 • 3 min read

Quick Take: COMPASS Pathways has partnered with the South London Maudsley NHS Foundation Trust to advance psychedelic research and develop new mental health models for the UK. COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has signed a Memorandum of Understanding (MoU)…

Osmind Closes $15 Million Series A Round to Help Clinicians and Researchers Bring Innovative Mental Health Treatments to More Patients

Jul 2 • 5 min read

Quick Take: The funding comes from a number of angel investors with experience in the industry. Funding will support expansion of Osmind’s neuropsychiatry software platform and team growth Osmind, a healthcare technology company building the first digital infrastructure for neuropsychiatry, closed $15 million in Series A funding to further develop and expand its electronic health…

Tryp Therapeutics Partners with Alcami for Proprietary Formulations

Jun 29 • 3 min read

Quick Take: Tryp Therapeutics has partnered with Alcami Corporation to develop oral formulations for Tryp’s psilocybin active pharmaceutical ingredient. Tryp Therapeutics (CSE:TRYP), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with Alcami Corporation (Alcami”), a global pharmaceutical contract development and manufacturing organization (CDMO), to support the…

COMPASS Pathways completes COMP360 psilocybin therapy administration

Jun 28 • 3 min read

Quick Take: COMPASS Pathways has completed their flagship COMP360 psilocybin therapy administration for 216 patients. COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has completed psilocybin administration to the target 216 patients in its phase IIb clinical trial…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441